Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes

被引:57
作者
Danielsson, Pernilla
Janson, Annika
Norgren, Svante
Marcus, Claude
机构
[1] Karolinska Univ Hosp, Dept Pediat, Clintec, S-14186 Huddinge, Sweden
[2] Karolinska Univ Hosp, Natl Childhood Obes Ctr, S-14186 Huddinge, Sweden
关键词
D O I
10.1210/jc.2007-0826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Behavioral treatment of children suffering from hypothalamic obesity or uncomplicated obesity in combination with syndromes that aggravate this condition has proven to be ineffective. The combination of comorbidities and severe obesity lower the quality of these children's lives drastically. The present goal was to determine whether treatment with sibutramine has a beneficial effect on such children. Design and Subjects: A double-blind, placebo-controlled, cross-over study ( 20 + 20 wk), followed by a 6-month open phase, was performed. The primary indicator of efficacy was the body mass index (BMI) SD score (SDS) value, which was analyzed using an ANOVA repeated-measures design [ intention to treat (ITT)]. The 50 children (7-20 yr of age) involved included 22 with hypothalamic obesity and 28 with uncomplicated obesity plus aggravating syndromes. Forty-five patients completed the first phase, and 42 participated in the entire study. Results: The group that initially received the placebo demonstrated an insignificant decrease (- 0.06) in BMI SDS during this treatment but a significant decrease (- 0.68; P < 0.001) when treated with sibutramine. The other group demonstrated a reduction in their BMI SDS of -0.72 during administration of sibutramine and a rebound of + 0.43 when placed on the placebo ( P < 0.001 in both cases). The response of children with hypothalamic obesity was also significant but was less pronounced than that of children with nonhypothalamic obesity. During the open phase, a continuous reduction in weight was observed. The treatment was tolerated well. Conclusion: The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial.
引用
收藏
页码:4101 / 4106
页数:6
相关论文
共 25 条
  • [1] Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial
    Berkowitz, RI
    Wadden, TA
    Tershakovec, AM
    Cronquist, JL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14): : 1805 - 1812
  • [2] Effects of sibutramine treatment in obese adolescents - A randomized trial
    Berkowitz, Robert I.
    Fujioka, Ken
    Daniels, Stephen R.
    Hoppin, Alison G.
    Owen, Stanford
    Perry, Arlette C.
    Sothern, Melinda S.
    Renz, Cheryl L.
    Pirner, Mark A.
    Walch, Julia K.
    Jasinsky, Olga
    Hewkin, Ann C.
    Blakesley, Vicky A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 145 (02) : 81 - 90
  • [3] BRAY GA, 1984, PEDIATR ANN, V13, P525
  • [4] Establishing a standard definition for child overweight and obesity worldwide: international survey
    Cole, TJ
    Bellizzi, MC
    Flegal, KM
    Dietz, WH
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7244): : 1240 - 1243
  • [5] Cardiovascular effects of sibutramine in the treatment of obese adolescents: Results of a randomized, double-blind, placebo-controlled study
    Daniels, Stephen R.
    Long, Barbara
    Crow, Scott
    Styne, Dennis
    Sothern, Melinda
    Vargas-Rodriguez, Ileana
    Harris, Lisa
    Walch, Julia
    Jasinsky, Olga
    Cwik, Kristine
    Hewkin, Ann
    Blakesley, Vicky
    [J]. PEDIATRICS, 2007, 120 (01) : E147 - E157
  • [6] Overweight children and adolescents.
    Dietz, WH
    Robinson, TN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (20) : 2100 - 2109
  • [7] Monogenic obesity in humans
    Farooqi, IS
    O'Rahilly, S
    [J]. ANNUAL REVIEW OF MEDICINE, 2005, 56 : 443 - +
  • [8] Use of sibutramine in obese Mexican adolescents:: A 6-month, randomized, double-blind, placebo-controlled, parallel-group trial
    Garcia-Morales, Leticia M.
    Berber, Arturo
    Macias-Lara, Cecilia C.
    Lucio-Ortiz, Claudia
    Del-Rio-Navarro, Blanca E.
    Dorantes-Alvarez, Luis M.
    [J]. CLINICAL THERAPEUTICS, 2006, 28 (05) : 770 - 782
  • [9] Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy:: Analysis of KIGS (Pfizer International Growth Database)
    Geffner, M
    Lundberg, M
    Koltowska-Häggström, M
    Abs, R
    Verhelst, J
    Erfurth, EM
    Kendall-Taylor, P
    Price, DA
    Jonsson, P
    Bakker, B
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (11) : 5435 - 5440
  • [10] Treatment of obese adolescents with sibutramine: A randomized, double-blind, controlled study
    Godoy-Matos, A
    Carraro, L
    Vieira, A
    Oliveira, J
    Guedes, EP
    Mattos, L
    Rangel, C
    Moreira, RO
    Coutinho, W
    Appolinario, JC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) : 1460 - 1465